Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT04240886) enrolled 21 adults who received the study drug fosmanogepix (also called APX001) as part of Cohort A. The trial was investigating a treatment for serious fungal infections, and it tracked what happened to participants over roughly six weeks (up to Day 42). Of the 21 people who started the treatment phase, 11 completed it and 10 did not. The trial measured things like survival, how the fungal infection responded, and what medical events occurred during the study. The reported data shows that 25% of participants (that is, roughly 1 in 4) died at some point between their first dose and Day 42. When an independent review committee assessed how each participant's fungal infection had responded by the end of their treatment, the reported data shows that 20% had a complete response (all signs of infection resolved), 20% had a partial response (improvement but not full resolution), 10% had a stable response (little change), 30% had disease progression (the infection got worse), and 20% had died. Combining these categories, 40% were counted as "treatment successes" (complete or partial response) and 60% were counted as "treatment failures" (stable, worsening, or death). The reported data also shows that all 21 participants experienced at least one adverse event (an unexpected medical occurrence during the study), and 13 of the 21 experienced a serious adverse event — meaning a medical event considered significant, such as one requiring hospitalisation. Five participants had a clinically significant abnormality in vital signs (such as blood pressure, heart rate, or temperature), and 12 participants had a clinically significant abnormality in laboratory test results. These figures describe what was observed and recorded; they do not on their own tell us what caused these events. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 40203286) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Rare Disease Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are a man or woman aged 18 or older.
- You have been diagnosed with, or are strongly suspected to have, a serious invasive fungal infection caused by mold, such as Aspergillus or similar fungi (for example, Fusarium, Mucor, or Rhizopus).
- Your current standard antifungal treatments are not working well, cannot be used safely, or are not expected to work for you — for example, because the fungus is resistant to them, you cannot tolerate them, or guidelines suggest they are not suitable for your situation.
- Your doctor believes the study drug (APX001) may offer an advantage over standard treatments for your specific situation — for example, because of concerns about safety, drug interactions, or because the infection is in a location that standard treatments cannot reach well (confirm with trial site).
Who may not be able to join:
- You have a blood cancer that is not responding to treatment.
- Your fungal infection is a long-term (chronic) form of aspergillosis, a fungal ball (aspergilloma), or an allergic lung condition caused by Aspergillus.
- You have received certain antifungal medicines (taken by mouth, by injection, or inhaled) in the 120 hours (5 days) before starting the study drug — unless the fungus causing your infection is known to be resistant to those medicines (confirm with trial site).
- You have significant liver problems or poor liver function.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of Participants Who Died After the First Dose of Study Drug Through Day 42
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.